<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00129844</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-0227</org_study_id>
    <nct_id>NCT00129844</nct_id>
  </id_info>
  <brief_title>Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer</brief_title>
  <official_title>Randomized Phase II Trial of Single Agent Motexafin Gadolinium for Second Line Treatment of Non-Small-Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of MGd in non-small-cell lung cancer&#xD;
      (NSCLC) when given alone, and to evaluate the difference between two dosing regimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outline:&#xD;
&#xD;
      Two-arm, open-label, randomized, 2-stage Phase II trial. Patients will be randomized on the&#xD;
      first stage to 1 of 2 treatment arms:&#xD;
&#xD;
      Arm A - 10 mg/kg MGd once per week&#xD;
&#xD;
      Arm B - 15 mg/kg MGd once every 3 weeks&#xD;
&#xD;
      Patients will be treated on 3 week cycles, up to a maximum of 8 cycles (24 weeks). Patients&#xD;
      with either objective response or stable disease after 2 cycles will receive up to 8 cycles&#xD;
      of therapy. Patients with progressive disease will be terminated from the study.&#xD;
&#xD;
      At the end of Stage I, both treatment arms will be evaluated, and only the arm(s) that&#xD;
      demonstrate at least one response (Complete Response or Partial Response) will proceed to&#xD;
      Stage II. If both arms demonstrate a response, then both will proceed to Stage II.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the response rates of two different MGd dosing regimens for the treatment of NSCLC</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To select the most effective regimen based on tumor response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of 2 dosing regimens of MGd in NSCLC patients</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Adenocarcinoma</condition>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <condition>Lung Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motexafin Gadolinium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of NSCLC&#xD;
&#xD;
          -  Unresectable locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC patients who&#xD;
             have received one prior platinum-based chemotherapy regimen&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria&#xD;
&#xD;
          -  ECOG performance status score of 0 or 1&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laboratory values of:&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1500/ul;&#xD;
&#xD;
               -  Platelet count &lt; 75,000/ul;&#xD;
&#xD;
               -  Hemoglobin &lt; 10 gm/dl;&#xD;
&#xD;
               -  AST or ALT &gt; 3 x the upper limit of normal (ULN);&#xD;
&#xD;
               -  Alkaline phosphatase &gt; 5 x ULN;&#xD;
&#xD;
               -  Bilirubin &gt; 2 x ULN;&#xD;
&#xD;
               -  Serum creatinine &gt; 2.0 mg/dL.&#xD;
&#xD;
          -  Symptomatic or uncontrolled (untreated or treated and progressing) brain metastasis.&#xD;
&#xD;
          -  Evidence of meningeal metastasis.&#xD;
&#xD;
          -  Greater than one prior cytotoxic regimen (not counting adjuvant or neoadjuvant&#xD;
             cytotoxic chemotherapy if completed &gt; 12 months prior to cytotoxic regimen).&#xD;
&#xD;
          -  Chemotherapy, radiation therapy, experimental therapy, immunotherapy or systemic&#xD;
             biologic anticancer therapy within 21 days before beginning study treatment.&#xD;
&#xD;
          -  Significant weight loss &gt; 10% of body weight in preceding 6 weeks.&#xD;
&#xD;
          -  Treatment for another cancer within 3 years of enrollment, unless basal cell carcinoma&#xD;
             or cervical cancer in situ.&#xD;
&#xD;
          -  Myocardial infarction within 6 months of enrollment or congestive heart failure rated&#xD;
             New York Heart Association (NYHA) Class III or IV.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure &gt; 160 mm Hg and diastolic blood&#xD;
             pressure &gt; 110 mm Hg on maximal medical therapy).&#xD;
&#xD;
          -  Known history of porphyria (testing not required at screening visit).&#xD;
&#xD;
          -  Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing not&#xD;
             required at screening visit).&#xD;
&#xD;
          -  Known history of HIV infection (testing not required at screening visit).&#xD;
&#xD;
          -  Female who is pregnant or lactating (serum pregnancy test is required for all female&#xD;
             patients of childbearing potential).&#xD;
&#xD;
          -  Sexually active male or female of childbearing potential unwilling to use adequate&#xD;
             contraceptive protection.&#xD;
&#xD;
          -  Physical or mental condition that makes patient unable to complete specified follow-up&#xD;
             assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Natale, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Aptium Oncology, Inc. Cedars-Sinai Outpatient Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>August 10, 2005</study_first_submitted>
  <study_first_submitted_qc>August 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2005</study_first_posted>
  <last_update_submitted>August 19, 2008</last_update_submitted>
  <last_update_submitted_qc>August 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2008</last_update_posted>
  <keyword>Motexafin Gadolinium</keyword>
  <keyword>non-small cell, lung cancer</keyword>
  <keyword>Lung cancer</keyword>
  <keyword>cancer of the lung</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motexafin gadolinium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

